Journal ArticleRheumatology (Oxford) · December 1, 2019
Immune checkpoint inhibitors are novel biologic agents to treat cancer by inhibiting the regulatory interactions that limit T cell cytotoxicity to tumours. Current agents target either CTLA-4 or the PD-1/PD-L1 axis. Because checkpoints may also regulate au ...
Full textOpen AccessLink to itemCite